Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights
Esther Ganelin-Cohen, Yair Wexler, Sraya Kraus, Ayal Rozenberg · 2026
Read Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights by Esther Ganelin-Cohen, Yair Wexler, Sraya Kraus, Ayal Rozenberg (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13175832.txt.
Description
Esther Ganelin-Cohen and co-authors report real world outcomes for a drug used in children with multiple sclerosis in a 2026 study. The disease starts young in this group, with strong inflammation and hard choices about long term therapy. The drug, given as tablets in short courses, is not formally approved for children, so clinic data matter.
Records covered forty seven young patients at two centers, with thirty one on the drug and sixteen on standard therapies. Rates of no disease activity matched at one year, and scan results did not differ. Far fewer patients quit the tablet drug, and no severe side effects occurred. The authors back careful off label use in chosen cases.
Catalog record
| CREATOR | Esther Ganelin-Cohen, Yair Wexler, Sraya Kraus, Ayal Rozenberg |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |